Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus CEFTAZIDIME IN DEXTROSE CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus CEFTAZIDIME IN DEXTROSE CONTAINER.
ANSPOR vs CEFTAZIDIME IN DEXTROSE CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1-2 g intravenously every 8 hours.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic